RVL Pharmaceuticals (FRA:O1P) Total Stockholders Equity : €15.07 Mil (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is RVL Pharmaceuticals Total Stockholders Equity?

RVL Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2023 was €15.07 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. RVL Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2023 was €0.15. The ratio of a company's debt over equity can be used to measure how leveraged this company is. RVL Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2023 was 3.56.

RVL Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for RVL Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RVL Pharmaceuticals Total Stockholders Equity Chart

RVL Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Total Stockholders Equity

Get a 7-Day Free Trial

337.40

103.24

77.15

67.91

48.23

RVL Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Total Stockholders Equity	Get a 7-Day Free Trial															55.35	69.23	48.23	37.36	15.07

RVL Pharmaceuticals (FRA:O1P) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

RVL Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(15.069	-	0)	/	99.3922
	=	0.15

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

RVL Pharmaceuticals's Debt-to-Equity for the quarter that ended in Jun. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(53.492	+	0.177)	/	15.069
	=	3.56

RVL Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of RVL Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

RVL Pharmaceuticals (FRA:O1P) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RVL Pharmaceuticals PLC (FRA:O1P) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

RVLPQ:USA

Address

400 Crossing Boulevard, Bridgewater, NJ, USA, 08807

Website

https://www.rvlpharma.com

RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.

RVL Pharmaceuticals (FRA:O1P) Headlines

No Headlines